Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 063 JPY -4.17% Market Closed
Market Cap: 4.4T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Otsuka Holdings Co Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Common Shares Outstanding
ÂĄ540.4m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Takeda Pharmaceutical Co Ltd
TSE:4502
Common Shares Outstanding
ÂĄ1.6B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
7%
Daiichi Sankyo Co Ltd
TSE:4568
Common Shares Outstanding
ÂĄ1.9B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
10%
S
Shionogi & Co Ltd
TSE:4507
Common Shares Outstanding
ÂĄ850.7m
CAGR 3-Years
41%
CAGR 5-Years
22%
CAGR 10-Years
10%
Chugai Pharmaceutical Co Ltd
TSE:4519
Common Shares Outstanding
ÂĄ1.6B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
12%
Astellas Pharma Inc
TSE:4503
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.4T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co. Ltd. began its journey in 1921 as a small chemicals company in Naruto, Japan. Its evolution from those humble beginnings to a global pharmaceutical giant is marked by its relentless commitment to innovation and expansion. Today, Otsuka operates as a holding company, orchestrating a diversified portfolio across pharmaceuticals, nutraceuticals, consumer products, and medical devices. It has cultivated a unique philosophy: a balance between large-scale operations and niche markets. The company’s pharmaceutical sector, its most significant revenue contributor, is driven largely by advancements in CNS (central nervous system) treatments and nephrology. The success of its flagship product, Abilify, a leading antipsychotic, underscores Otsuka’s ability to combine market demands with cutting-edge research to sustain growth and profitability. In parallel, Otsuka nurtures its nutraceuticals wing, embodied by its signature Pocari Sweat and SoyJoy brands. These products epitomize the company’s strategy of creating and expanding niche markets, offering health-oriented products that resonate with evolving consumer health trends. This diversification into consumer products and nutraceuticals not only complements its pharmaceutical endeavors but also mitigates risks by tapping into varied revenue streams. By focusing on health and wellness broadly, Otsuka Holdings strategically positions itself to navigate the complexities of the global healthcare market, ensuring a resilient business model. Through this multifaceted approach, Otsuka sustains its growth, reaffirming its legacy as a dynamic and globally influential company.

Intrinsic Value
9 387.89 JPY
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
540.4m JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Common Shares Outstanding amounts to 540.4m JPY.

What is Otsuka Holdings Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%

Over the last year, the Common Shares Outstanding growth was 0%.

Back to Top